PLSE

Pulse Biosciences is not an operating business in any conventional sense — it is a clinical-stage medical-device bet. FY2025 revenue was just $350K against a net loss of $72.8M, and the company has produced essentially zero meaningful revenue across the last five years ($0 in both FY2023 and FY2024). Management says so plainly in the 10-K: it is 'a novel ablation company with no significant revenue producing operations at present,' has 'incurred significant operating losses in each year since inception,' and 'may never become profitable.' The accumulated deficit of -$463M underscores how much capital has already been consumed pursuing the Nano-pulse Stimulation (NPS/nsPFA) platform. Derived margins (operating margin -21,982%, net margin -20,795%) are not analytically meaningful — they simply confirm there is no revenue base to value against.

The entire investment case rests on optionality: the 2022 pivot to atrial fibrillation, which management frames as a '>$3.0 billion addressable market' with ~1.9M US patients diagnosed annually, plus the Vybrance surgical soft-tissue ablation product. That is a real and large market, and the balance sheet is clean — $80.7M cash, only $13.9M total liabilities, liabilities/equity of 0.17x. But none of that can be valued from the numbers provided. The outcome hinges on clinical-trial readouts and FDA clearance that these figures cannot assess. This is the textbook 'unknowable risk' case.